Clinical Trial Update: Phase 2 Study of MM-093 to Treat Patients With Uveitis [Phase 2]

View source ↗

Summary

Phase 2 study of MM-093 for uveitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveitis

Drugs mentioned

• MM-093 (MM-093)

Snippet

Sponsor: Merrimack Pharmaceuticals | Conditions: Uveitis | Phase 2 | Status: COMPLETED